Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.

Timeline

Start

2023-04-04

Primary completion

2025-06-30

Completion

2025-06-30

Outcome

Outcome not reported

Stopped: “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.”

Drugs

Indications